The conjugated agents ado-trastuzumab-emtansine (T-DM1) and tratuzumab-hyaluronidase-oysk were approved for markets by the USA, Europe, and China for the treatment of HER2-positive breast cancer in 2019, but they have been rarely tried for mCRC. The gene discussed is ERBB2; the disease is breast cancer.